These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 15829330

  • 1. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.
    Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, So T, Sugio K, Yasumoto K.
    Lung Cancer; 2005 May; 48(2):281-9. PubMed ID: 15829330
    [Abstract] [Full Text] [Related]

  • 2. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
    Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N.
    Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
    [Abstract] [Full Text] [Related]

  • 3. Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals.
    Karanikas V, Soukou F, Kalala F, Kerenidi T, Grammoustianou ES, Gourgoulianis KI, Germenis AE.
    Clin Immunol; 2008 Nov; 129(2):230-40. PubMed ID: 18789878
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, Asanuma H, Takahashi A, Michifuri Y, Nakamori K, Nagai I, Sato N, Hiratsuka H.
    Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
    [Abstract] [Full Text] [Related]

  • 10. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
    Yagihashi A, Asanuma K, Kobayashi D, Tsuji N, Shijubo Y, Abe S, Hirohashi Y, Torigoe T, Sato N, Watanabe N.
    Lung Cancer; 2005 May; 48(2):217-21. PubMed ID: 15829321
    [Abstract] [Full Text] [Related]

  • 11. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.
    Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, Wada H.
    Clin Cancer Res; 2007 Dec 01; 13(23):6938-46. PubMed ID: 18056168
    [Abstract] [Full Text] [Related]

  • 12. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient.
    Nagata Y, Hanagiri T, Takenoyama M, Fukuyama T, Mizukami M, So T, Ichiki Y, Sugaya M, Sugio K, Yasumoto K.
    Clin Cancer Res; 2005 Jul 15; 11(14):5265-72. PubMed ID: 16033845
    [Abstract] [Full Text] [Related]

  • 13. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
    Kitamura H, Torigoe T, Honma I, Asanuma H, Nakazawa E, Shimozawa K, Hirohashi Y, Sato E, Sato N, Tsukamoto T.
    Urology; 2006 May 15; 67(5):955-9. PubMed ID: 16635519
    [Abstract] [Full Text] [Related]

  • 14. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma.
    Fukuyama T, Hanagiri T, Takenoyama M, Ichiki Y, Mizukami M, So T, Sugaya M, So T, Sugio K, Yasumoto K.
    Cancer Res; 2006 May 01; 66(9):4922-8. PubMed ID: 16651449
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Up-regulation of survivin mRNA might be a marker for non-invasive detection of non-small cell lung cancer rather than for prognosis.
    Warnecke-Eberz U, Baldus SE, Bollschweiler E, Hoelscher AH, Metzger R.
    Anticancer Res; 2008 May 01; 28(3A):1525-9. PubMed ID: 18630507
    [Abstract] [Full Text] [Related]

  • 17. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG, Korn S, Micke P, Becker K, Huber C, Wölfel T, Buhl R.
    Lung Cancer; 2007 Oct 01; 58(1):88-94. PubMed ID: 17599645
    [Abstract] [Full Text] [Related]

  • 18. Inhibitors of apoptosis proteins in human cervical cancer.
    Espinosa M, Cantú D, Herrera N, Lopez CM, De la Garza JG, Maldonado V, Melendez-Zajgla J.
    BMC Cancer; 2006 Feb 27; 6():45. PubMed ID: 16504151
    [Abstract] [Full Text] [Related]

  • 19. A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.
    Zhou Q, Guo AL, Xu CR, An SJ, Wang Z, Yang SQ, Wu YL.
    Clin Exp Immunol; 2008 Sep 27; 153(3):392-400. PubMed ID: 18803763
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH, Wang SF, Yu L, Wang J, Chang H, Yan WL, Zhang J, Fu K.
    Lung Cancer; 2008 Oct 27; 62(1):113-9. PubMed ID: 18550205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.